Cargando…

Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study

The aims of this multicentric retrospective study were to assess in a real-world setting the effectiveness and safety of canagliflozin 100 mg/d (CANA100) as an add-on to the background antihyperglycemic therapy, and to evaluate the intensification of prior sodium–glucose co-transporter type 2 inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gorgojo-Martínez, Juan J., Gargallo-Fernández, Manuel A., Galdón Sanz-Pastor, Alba, Antón-Bravo, Teresa, Brito-Sanfiel, Miguel, Wong-Cruz, Jaime
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408903/ https://www.ncbi.nlm.nih.gov/pubmed/32708943 http://dx.doi.org/10.3390/jcm9072275

Ejemplares similares

Predictive Factors of Renal Function Decline in Patients with Type 2 Diabetes Treated with Canagliflozin in the Real-Wecan Study
por: Gorgojo-Martinez, Juan J., et al.
Publicado: (2022)

Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study
por: Gorgojo-Martinez, Juan J., et al.
Publicado: (2023)

Short-term outcomes of type 2 diabetes mellitus patients treated with canagliflozin in real-world setting
por: Baruah, Manash P., et al.
Publicado: (2016)

Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis
por: Buysman, Erin K., et al.
Publicado: (2015)

Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan
por: Kadowaki, Takashi, et al.
Publicado: (2022)

Efficacy and Safety of Canagliflozin 300 mg in Overweight and Obese Type 2 Diabetes Mellitus Patients in a Real-world Setting: COLOR Study
por: Aneja, Pankaj, et al.
Publicado: (2019)

Evaluation of Service-Learning in Project WeCan under COVID-19 in a Chinese Context
por: Leung, Hildie, et al.
Publicado: (2021)

Health care provider experience with canagliflozin in real-world clinical practice: favorability, treatment patterns, and patient outcomes
por: Bolge, Susan C, et al.
Publicado: (2017)

Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance
por: Inagaki, Nobuya, et al.
Publicado: (2021)

Comprehensive workplace intervention for cancer prevention in China (WECAN): protocol for a stepped-wedge, cluster-randomised controlled trial
por: Li, Yuan, et al.
Publicado: (2023)

Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain
por: Sempere, Angel P., et al.
Publicado: (2021)

Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain
por: Escobar Álvarez, Y., et al.
Publicado: (2021)

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
por: Woo, Vincent, et al.
Publicado: (2018)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
por: Triplitt, Curtis, et al.
Publicado: (2015)

Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
por: Santos, José Ramón, et al.
Publicado: (2023)

Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study)
por: Rodríguez-Nieto, Maria Jesus, et al.
Publicado: (2023)

Drugs: Real World Outcomes
por: Peters, Dene C., et al.
Publicado: (2014)

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
por: Bays, Harold E, et al.
Publicado: (2014)

Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study
por: Mezquita-Raya, Pedro, et al.
Publicado: (2015)

Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain
por: Norrbacka, Kirsi, et al.
Publicado: (2021)

Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study
por: Duque, Natalia, et al.
Publicado: (2021)

Progression from prediabetes to type 2 diabetes mellitus in adolescents: a real world experience
por: Weiner, Alyson, et al.
Publicado: (2023)

The continuum of ovarian response leading to BIRTH, a real world study of ART in Spain
por: Ferrando, Marcos, et al.
Publicado: (2020)

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain
por: Escobar Cervantes, Carlos, et al.
Publicado: (2022)

Real-world outcomes of a clinical decision support system for diabetic retinopathy in Spain
por: Romero-Aroca, Pedro, et al.
Publicado: (2022)

Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study
por: Pericay, Carles, et al.
Publicado: (2023)

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
por: Rodbard, H. W., et al.
Publicado: (2016)

Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS)
por: Hassanein, Mohamed, et al.
Publicado: (2017)

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
por: Stenlöf, K, et al.
Publicado: (2013)

A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus
por: Nardolillo, AnneMarie, et al.
Publicado: (2014)

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
por: Yagi, Shusuke, et al.
Publicado: (2017)

Social Validity in Spain of the Mantente REAL Prevention Program for Early Adolescents: Social Validity of Mantente Real in Spain
por: Cutrín, Olalla, et al.
Publicado: (2022)

Identifying “Real” Patients in the Real World
por: Callahan, Sean J.
Publicado: (2020)

Effects of water‐soluble mangosteen extract on cognitive function and neuropsychiatric symptoms in patients with mild to moderate Alzheimer's disease (WECAN‐AD): A randomized controlled trial
por: Muangpaisan, Weerasak, et al.
Publicado: (2022)

Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience
por: Marín-Pozo, Juan F., et al.
Publicado: (2016)

Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain
por: Gomez-Peralta, Fernando, et al.
Publicado: (2020)

Heterologous COVID-19 Vaccination in Spain: A Case Study of Individual Autonomy in the Real World
por: Dal-Ré, Rafael, et al.
Publicado: (2022)

Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients
por: Escalera, Carlos Rodríguez, et al.
Publicado: (2022)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
por: Iijima, Hiroaki, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_albh7n4k77gps1buomi3nn4a8s